Announcement PDF RNS Number : 0805K N4 Pharma PLC 27 May 2025 27 May 2025 N4 Pharma plc ("N4 Pharma" or the "Company") Establishment of New Senior Leadership Team N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the formation of a new Senior Leadership Team comprising leading expert consultants in drug development and research, commercial strategy, and pharmaceutical manufacturing. The Senior Leadership Team will support the Board in delivering N4 Pharma's strategic and scientific objectives set out by the Company at the recent successful placing. The focus of the use of proceeds is to advance the development of Nuvec® as a novel delivery platform and build out the commercial data room in order to strengthen discussions with potential commercial partners. The Senior Leadership Team, which reports to the Chief Executive Officer, comprises the following members: Dr Fiona McLaughlin - Head of Research and Development Dr Fiona McLaughlin is a highly experienced oncology drug developer and independent consultant, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Fiona started her career at GSK and has subsequently held leadership positions in multiple biotech companies, including CSO of Avacta Therapeutics, VP New Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma plc and Director of Pre-clinical Development at BTG plc (now part of Boston Scientific). She is also a non-executive director of Hox Therapeutics. Fiona received a PhD from the Haematology Department at Cambridge University and has a BSc in Biochemistry from Glasgow University. Mark Edbrooke - Head of Strategy Mark Edbrooke, PhD is an independent scientific consultant with a broad experience in pharmaceutical research and development. During 25 years at GlaxoSmithKline, he ran a transnational functional genomics department, and then set up and led GSK's therapeutic nucleic acid unit. He then joined AstraZeneca's Oncology Division for three years, working with Ionis and Moderna. Mark currently has a portfolio of clients, including UK and US-based investment companies, UK and European-based universities, and small biotechs, including being Head of Translational Research at Argonaute RNA Ltd., and on the Senior Advisory Board for Deep Genomics. Dr Simon Bennett - Commercial Director Dr Simon Bennett is an independent consultant with over 28 years of experience in the biopharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford. Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC) Dr Margaret Courtney is an independent consultant with over 25 years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialisation. Margaret has worked in management positions in small biotech companies to large pharmaceutical organisations, and following on from her pharmacy degree and doctoral studies, has developed specific expertise in drug delivery systems. Currently, she is working with a range of clients and providing CMC strategic advice as well as selection and management of contract organisations. Nigel Theobald, Chief Executive Officer of N4 Pharma, commented: "The Senior Leadership Team that we have formed to help us swiftly deliver on our strategic and scientific goals is a world-class group of consultants with extensive experience in drug development, manufacturing and commercialisation. These appointments bring essential expertise to advance the Nuvec® platform towards our goal of commercial partnerships as well as build a pipeline of novel, highly valuable RNA therapeutic concepts for N4 Pharma to develop inhouse. "Each member of the Senior Leadership Team brings deep expertise and a proven track record in their respective fields. Their involvement with N4 Pharma on the development of Nuvec® is a strong endorsement of the progress to date and a clear demonstration of confidence in its future potential. "The Board looks forward to their valuable guidance as we continue to unlock the full potential of Nuvec® as a novel delivery platform toenable advanced therapies for cancer and other diseases." - Ends For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Via N4 Pharma Investor Hub:investors.n4pharma.com Submit your questions directly to the management team via the N4 Pharma Investor Hub https://investors.n4pharma.com/link/pegvRy SP Angel CorporateFinance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope Tel: +44 (0)20 3657 0050 Northstar Communications Limited Investor Relations Sarah Hollins Tel: +44 (0)113 730 3896 About N4 Pharma N4 Pharma is a pre-clinical biotech company developing Nuvec®,its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. For further information on the Company visitwww.n4pharma.comor sign up athttps://investors.n4pharma.com/auth/signup. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRABGGDUISDDGUL